Wealth Architects LLC Sells 198 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Wealth Architects LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,160 shares of the biopharmaceutical company’s stock after selling 198 shares during the quarter. Wealth Architects LLC’s holdings in Gilead Sciences were worth $569,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. TCTC Holdings LLC grew its position in Gilead Sciences by 10.0% during the 4th quarter. TCTC Holdings LLC now owns 2,764 shares of the biopharmaceutical company’s stock worth $255,000 after acquiring an additional 251 shares during the last quarter. Signaturefd LLC grew its position in shares of Gilead Sciences by 5.1% in the 4th quarter. Signaturefd LLC now owns 22,062 shares of the biopharmaceutical company’s stock worth $2,038,000 after buying an additional 1,062 shares during the last quarter. Cibc World Markets Corp grew its position in shares of Gilead Sciences by 236.8% in the 4th quarter. Cibc World Markets Corp now owns 661,209 shares of the biopharmaceutical company’s stock worth $61,076,000 after buying an additional 464,874 shares during the last quarter. GLOBALT Investments LLC GA grew its stake in Gilead Sciences by 20.3% in the fourth quarter. GLOBALT Investments LLC GA now owns 48,659 shares of the biopharmaceutical company’s stock worth $4,495,000 after purchasing an additional 8,204 shares during the period. Finally, SlateStone Wealth LLC bought a new stake in Gilead Sciences in the fourth quarter worth $237,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of research analyst reports. Mizuho upped their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. The Goldman Sachs Group increased their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Finally, JPMorgan Chase & Co. increased their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.52.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have sold 302,785 shares of company stock worth $30,503,250. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $111.44 on Monday. The stock has a market cap of $138.78 billion, a PE ratio of 301.19, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The business has a 50-day simple moving average of $101.82 and a 200-day simple moving average of $92.92. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.